Hims & Hers Health, Inc. (HIMS) closed at $29.72 in the latest trading session, marking a -0.3% move from the prior day. This move lagged the S&P 500's daily gain of 0.61%. Elsewhere, the Dow gained 0.3%, while the tech-heavy Nasdaq added 1.28%.The the stock of company has risen by 5.9% in the past month, leading the Medical sector's gain of 1.64% and the S&P 500's gain of 2.08%.Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings d ...

Hims & Hers Health, Inc. (NYSE: HIMS ) demonstrated a robust start into 2025 with a 15.5% YTD rally. My intrinsic value calculation suggests that there is still massive potential upside even after the powerful rally of the first half ofAs an investor who started my path five years ago with my own capital, I represent a blend of hands on experience and academic background in corporate finance. Due to my relatively young age I thrive on discovering long-duration growth opportunities and actively seek out oppo ...

A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of companies selling (or hoping to sell) semaglutide and related drugs for treating diabetes and losing weight. As of 11 a.m. ET, shares of Novo Nordisk (NVO -4.61%) are down 4.2%, and Hims & Hers Health (HIMS -2.52%) stock is getting walloped for a 5.8% loss. In contrast, shares of Viking Therapeutics (VKTX 4.65%) are up a modest 3.3%.And why? As CNBC reports today, the Biden administration ...

Hims & Hers Health (HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth company has been growing at a fast rate, making it one of the best stocks to own in healthcare of late.But while the business is growing, investors should be careful not to overlook the challenges the company is facing. Not only is competition potentially ramping up, but a key growth catalyst for the business could be going away soon. Entering trading this week, the stock has fallen b ...

The focus is on GLP-1s, but there's more to Hims & Hers than one product.Hims & Hers (HIMS -4.12%) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the stock. But the business is about much more than just one product, and Travis Hoium explains why investors should expect an expanded platform in 2025.*Stock prices used were end-of-day prices of Jan. 8, 2025. The video was published on Jan. 10, 2025. ...

Company Overview - Hims & Hers (NYSE: HIMS) is a company leveraging the trend of telehealth to provide easier access to healthcare services [1] - The company's business model is under scrutiny for its durability and competitive advantage [1] Analyst Background - Oliver Rodzianko is an investment analyst specializing in the technology sector, with expertise in AI, semiconductors, software, and renewable energy [1] - He focuses on companies with resilient management and lasting competitive advantages [1] - Rodzianko's investment strategy involves value trading at inflection points without leverage or short interest, typically holding investments for one to two years [1] - He employs advanced risk-mitigation strategies to protect against and capitalize on recessions and market crashes [1]

Hims & Hers Health has donated $1 million to President-elect Donald Trump's inauguration fund, CNBC confirmed Tuesday.The company, which offers a range of direct-to-consumer treatments for conditions like weight loss, erectile dysfunction and hair loss, is the latest in a string of tech companies that have tried to curry favor with the incoming administration. OpenAI CEO Sam Altman and Meta both announced $1 million donations to the inaugural fund late last year, and Amazon and Apple CEO Tim Cook have also ...

Company Overview - Hims & Hers Health is a telehealth company founded in 2017, focusing on delivering medication for stigmatized conditions without requiring direct interaction with a doctor [3] Investment Position - The company represents the largest position in the portfolio at 15% [3] Industry Context - The company operates in the telehealth industry, which has been growing due to increased demand for remote healthcare services [3]

Hims & Hers stock is full of noise, but what's the signal for investors?Hims & Hers Health (HIMS -7.67%) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a growth stock investors should watch, which Travis Hoium explains in this video.*Stock prices used were end-of-day prices of Dec. 18, 2024. The video was published on Dec. 19, 2024. ...

One of 2024's best stocks is at an intriguing entry pointHims & Hers Health Inc (NYSE:HIMS) stock is sitting out the broad market rally today, last seen down 8.4% to trade at $26.15. The personalized healthcare company -- a key player in the weight loss drug craze -- is taking a hit after the Food and Drug Administration (FDA) announced Eli Lilly's (LLY) weight-loss drug shortage was resolved. HIMS is on track for its worst single-session decline since Nov. 14, when Amazon.com (AMZN) entered the telehealth ...